Epitracker aims to help people live longer and healthier. Our longevity program has resulted in discovery of approximately one hundred promising molecules, including our lead micronutrient, ETI-101, to protect cells against the aging process. ETI-101 is being advanced to market through an Epitracker spinout, Seraphina Therapeutics, Inc. Additional compounds, including ETI-1029 and ETI-1080, are being advanced to support healthy aging,
Promising molecules to expand longevity
Our longevity compound library includes molecules that may help to detect, prevent, and treat key conditions that impair our longevity and quality of life, including:
ETI-101 for anemia of inflammation
ETI-101 is a small molecule targeting both clinical diseases and anti-aging mechanisms.
Anemia of Inflammation
As we age, we are more likely to develop chronic, low-lying systemic inflammation and fragile red blood cells, which results in anemia of inflammation. Anemia of inflammation is the most common type of anemia in the elderly. An estimated 77% of people older than 85 years old have anemia of inflammation, which increases the risks of:
ETI-101 has demonstrated repeatable efficacy across multiple mammalian models. ETI-101 attenuated the following indices in models with disease:
- Alleviated anemia (raised hemoglobin, hematocrit, and RBCs)
- Lowered inflammation (lowered globulins, MCP-1, IL-6)
- Lowered liver iron deposition in animal model for NASH
- Reduced liver fibrosis severity in animal model for NASH
- Lowered cholesterol, triglycerides, glucose and insulin
ETI-101 Healthy Aging Mechanisms
Our studies to date support ETI-101's anti-aging mechanisms, including:
- Improved cell membrane integrity/resilience
- Improved mitochondrial function
- Upregulation of the AMP-activated protein kinase (AMPK) signaling pathway
- AMPK activation (phosphorylation)
- Predicted raised levels of geroprotective miRNA
ETI-101 Cell-Based Activity
In human cell-based systems mimicking a variety of disease states, ETI-101 has demonstrated significant dose-response anti-inflammatory and antifibrotic activity, including:
- Lowered MCP-1 (a pro-inflammatory chemokine)
- Lowered secreted immunoglobulin G
- Lowered Collagen I
- Lowered fibroblast proliferation
ETI-101 has a strong safety profile. To date, ETI-101 has demonstrated no cytotoxicity (using 12 human cell systems at four concentrations) and no off-target effects (using 78 functional assays at 10 concentrations).
ETI-035 and ETI-059 for cachexia
ETI-035 and ETI-059 are being developed to treat aging-associated weakness and wasting of the body (cachexia) due to severe illness, poor appetite and cognitive impairment. ETI-035 and ETI-059 are partial cannabanoid 1 receptor (CNR1) agonists that may help increase appetite and cognitive function in the elderly.
ETI-1029 and ETI-1080 for inflammaging
ETI-1029 is an amino acid that hat decreases with age in long-lived mammals. ETI-1029 is demonstrating mitochondrial protective and anti-inflammatory activities in human cell systems mimicking lipid peroxidation and inflammation. ETI-1029 significantly reduced macrophages, inflammatory cells that increase with age and have been proposed as a key players in inflammaging.
ETI-1080 is a xenobiotic that decreases with age in long-lived mammals. Higher blood levels of ETI-1080 are associated with lower glucose, cholesterol, triglycerides, insulin and liver enzymes; and higher red blood cells and hemoglobin.
As part of a Phase II Small Business Innovation Research (SBIR) project set to be funded by the Office of Naval Research, Epitracker will be investigating the pharmacokinetics, activities and efficacies of ETI-1029 and ETI-1080 to better understand their potential as a means to prevent or treat inflammaging and other comorbidities of aging.